FDA accepts Neurovance's IND application for ADHD drug
The US Food and Drug Administration (FDA) has accepted Neurovance's investigational new drug (IND) application for EB-1020 SR, a norepinephrine and dopamine-preferring triple reuptake inhibitor.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: ADHD | Food and Drug Administration (FDA) | Investigational New Drugs | Neurology | Pharmaceuticals